CTIS2022-501480-41-00招募中1 期
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis. - TILD-21-01
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 759
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Subjects possess the ability to understand the requirements of the study, Subject has provided written informed consent as evidenced by signature on an informed consent form approved by an institutional review board/EC, Agree to abide by the study restrictions, scheduled treatment, laboratory assessments, other study procedures and return to the site for the required assessments, Subject with PsA who had met all eligibility criteria for the parent study, had completed the parent study treatment period and has not developed any parent protocol criteria for premature discontinuation of treatment or withdrawal from the study.
排除标准
- •Female subjects of childbearing potential who do not agree to abstain from heterosexual activity or practice a dual method of contraception, Female is pregnant or breastfeeding, or planning to become pregnant or initiate breastfeeding while enrolled in the study or up to 17 weeks after the last dose of IMP, Subject has previously been enrolled in this long-term extension study, Any condition that in the opinion of the Investigator represents an obstacle for study conduct and/or represents a potential unacceptable risk for the subject
研究者
相似试验
招募中
3 期
An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic ArthritisPsoriatic ArthritisJPRN-jRCT2031220622Oshima Satoe35
尚未招募
3 期
Study of long term Efficacy and Safety of Tildrakizumab in Subjects With Active Psoriatic Arthritis (PsA)CTRI/2024/07/071189Sun Pharmaceutical Industries Limited
招募中
1 期
A study to see how well KarXT is tolerated and how well tolerated it is when taken for long time in participants with psychosis associated with Alzheimer’s disease.Psychosis associated with Alzheimer’s DiseaseMedDRA version: 20.0Level: LLTClassification code: 10037234Term: Psychosis Class: 10037175MedDRA version: 20.0Level: PTClassification code: 10012271Term: Dementia Alzheimer's type Class: 100000004852CTIS2023-504151-27-00Karuna Therapeutics Inc.349
已完成
3 期
An open label extension study to evaluate long term use of a Food for Special Medical Purposes (FSMP) in patients with mild Alzheimer*s disease who completed the Souvenir II studyAlzheimerAlzheimers Disease10029305NL-OMON36704Danone Research - Centre for Specialised Nutrition120
进行中（未招募）
1 期
A study to determine the long term effect and safety of A4250 in treatment of children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2.Progressive Familial Intrahepatic Cholestasis Types 1 and 2MedDRA version: 20.0Level: PTClassification code 10076033Term: Progressive familial intrahepatic cholestasisSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2017-002325-38-DEAlbireo AB120